Semaglutide, delayed gastric emptying, and intraoperative pulmonary aspiration: a case report.
Can J Anaesth · 2023
Last updated 2026-05-28A 42-year-old patient taking weekly semaglutide injections for weight loss experienced delayed stomach emptying, leading to food remaining in the stomach even after an 18-hour fast. During a medical procedure, this caused food to be inhaled into the lungs, which was later cleared with a bronchoscopy. The patient recovered without symptoms after four hours.
AI summary of the abstract below.
| Journal | Can J Anaesth, 2023 |
|---|---|
| Citations | 144 |
| Relative citation ratio | 23.40 |
| NIH percentile | 100 |
| Molecules | semaglutide |
| Conditions studied | Gastroparesis |
Abstract
PURPOSE: We report a case in which the use of semaglutide for weight loss was associated with delayed gastric emptying and intraoperative pulmonary aspiration of gastric contents.
CLINICAL FEATURES: A 42-yr-old patient with Barrett's esophagus underwent repeat upper gastrointestinal endoscopy and ablation of dysplastic mucosa. Two months earlier, the patient had started weekly injections of semaglutide for weight loss. Despite having fasted for 18 hr, and differing from the findings of prior procedures, endoscopy revealed substantial gastric content, which was suctioned before endotracheal intubation. Food remains were removed from the trachea and bronchi using bronchoscopy. The patient was extubated four hours later and remained asymptomatic.
CONCLUSION: Patients using semaglutide and other glucagon-like peptide 1 agonists for weight management may require specific precautions during induction of anesthesia to prevent pulmonary aspiration of gastric contents.
Verbatim abstract via PubMed 36977934 ↗
Related research
- Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Once-Weekly Semaglutide in Adults with Overweight or Obesity.
- Semaglutide and Cardiovascular Outcomes in Obesity without Diabetes.
- A Placebo-Controlled Trial of Subcutaneous Semaglutide in Nonalcoholic Steatohepatitis.
- Tirzepatide versus Semaglutide Once Weekly in Patients with Type 2 Diabetes.
- Oral Semaglutide and Cardiovascular Outcomes in Patients with Type 2 Diabetes.
- Effects of Semaglutide on Chronic Kidney Disease in Patients with Type 2 Diabetes.
- Semaglutide in Patients with Heart Failure with Preserved Ejection Fraction and Obesity.